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Abstract 58 
Objective: Smokers are characterized by a low-grade systemic inflammatory state and an oxidant-antioxidant 59 
imbalance. Few human studies were conducted on the effects of resveratrol, a natural compound with anti-60 
inflammatory and antioxidant properties, and no trial on smokers has been performed to date. We evaluated 61 
whether resveratrol has beneficial effects on markers of inflammation and oxidative stress in smokers.  62 
Methods and Results: A randomized, double-blind, cross-over trial was performed in 50 healthy adult smokers: 63 
25 were randomly allocated to “resveratrol-first” (30-days: 500mg resveratrol/day, 30-days wash-out, 30-days 64 
placebo) and 25 to “placebo-first” (30-days placebo, 30-days wash-out, 30-days 500mg resveratrol/day).  65 
Resveratrol significantly reduced C-reactive protein (CRP) and triglyceride concentrations, and increased Total 66 
Antioxidant Status (TAS) values. After analyzing data with general linear models to assess period and carry-over 67 
effects, the ratios of the values after resveratrol to those after placebo were respectively: 0.47 (95%CI 0.38-0.59) 68 
–CRP- and 0.71 (95%CI 0.65-0.78) –triglycerides-, while TAS increased by 74.2 µmol/L (95%CI 60.8-87.6). 69 
Uric acid, glucose, insulin, cholesterol, liver enzyme concentrations, and weight, waist circumference, and blood 70 
pressure values did not significantly change after resveratrol supplementation. 71 
Conclusions: Because resveratrol has anti-inflammatory, anti-oxidant, and hypotriglyceridemic effects, its 72 
supplementation may beneficially affect the increased cardiovascular risk of healthy smokers. 73 
 74 
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Tobacco smoking is one of the most prevalent addictive habits, and it continues to be the second major cause of 87 
death in the world [1]. The consequences of long-term tobacco exposure, which predisposes individuals to 88 
chronic systemic diseases, such as cardiovascular diseases, are: an oxidant-antioxidant imbalance with increased 89 
products of lipid peroxidation and the depletion of antioxidants, a low-grade systemic inflammatory state with 90 
elevated concentrations of C-reactive protein (CRP), fibrinogen, and interleukin-6, and greater total numbers of 91 
circulating T-lymphocytes, and endothelial dysfunction with higher values of circulating adhesion molecules 92 
(intracellular adhesion molecule-1, selectins), and plasminogen activator inhibitor type I [1-3]. The potential 93 
benefits of dietary phenolics for smokers have been previously demonstrated [4]. A high concentration of 94 
flavonoids and other polyphenols was measured in red wine; furthermore, the reduction in cardiovascular risk by 95 
grapes and grape products is well known (a phenomenon known as the “French Paradox”). Resveratrol is a 96 
polyphenolic compound composed of two phenolic rings connected by a double bond and is found in several 97 
plants, particularly in grapes [5]. It exists in two isoforms, trans-resveratrol and cis-resveratrol, and the trans-98 
isomer is the more stable form [6]. A growing number of in vitro and animal studies have evaluated the 99 
beneficial properties of resveratrol [7-9]. The following activities have been identified for resveratrol: 100 
antioxidant, anti-inflammatory, anti-carcinogenic, anti-platelet aggregation, cardio-protective, neuro-protective, 101 
cartilage-protective, anti-aging activities. In addition, this compound has been shown to increase lifespan, act as 102 
an insulin sensitizer, reduce body weight, improve endothelial function, and mimic calorie restriction [7-10]. 103 
However, the number of published human clinical trials that have evaluated the in vivo effects of resveratrol is 104 
limited [10-11], although several ongoing trials at different stages are available in the clinical trials database 105 
[12]. The anti-inflammatory and antioxidant properties of resveratrol are particularly interesting, because these 106 
effects might account for many of the health benefits reported in laboratory models [10]. Ten individuals 107 
randomized to receive six weeks of an extract containing 40 mg resveratrol exhibited suppressed nuclear factor 108 
kappa B (NFκB) binding, decreased reactive oxygen species (ROS) generation, and reduced concentrations of 109 
tumor necrosis factor alpha, interleukin-6, and CRP with respect to the individuals receiving the placebo [13]. 110 
Similarly, a nutritional supplement containing resveratrol was found to have an acute anti-inflammatory and 111 
antioxidant effect after the ingestion of a high-fat, high-carbohydrate meal in 10 healthy females [14]. 112 
Resveratrol inhibits both the basal and stimulated release of inflammatory cytokines by alveolar macrophages in 113 
smokers [15]. To the best of our knowledge, no clinical trial on smokers has been performed to date.  114 
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This study tested the hypothesis that resveratrol when given orally to healthy adult smokers, induces a 115 
decrease in the levels of the inflammatory and oxidative mediators that characterize the low-grade systemic 116 
inflammatory state and the oxidant-antioxidant imbalance in smokers. 117 
 118 
Methods 119 
Recruitment of participants 120 
Fifty eligible healthy volunteers aged 20-50 years were recruited among individuals living in Piedmont 121 
(Northern Italy) in July 2011 - March 2012. The inclusion criteria were as follows: aged 20-50 years, current 122 
smoking (≥5 cigarettes/day and a smoking history of >20 packs/year), and mean alcohol consumption <30g/day. 123 
The exclusion criteria were as follows: current pregnancy, known hyperglycemia, hypertension, cardiovascular 124 
disease, impaired renal function, liver disease, or any other systemic chronic or acute conditions, the use of any 125 
drug except estrogen, being on a particular diet, the use of vitamins, other nutrients or dietary supplements 126 
during the previous six months, a body mass index (BMI)>30 kg/m2, and an inability to give informed consent. 127 
Design 128 
This study was a randomized, double-blind, placebo-controlled, cross-over trial. 129 
Outcomes 130 
The primary outcome was the change in the circulating concentrations of CRP after resveratrol supplementation 131 
relative to the change in the CRP concentrations after treatment with placebo. The secondary outcomes were the 132 
differences after resveratrol relative to the change after placebo supplementation in the circulating fasting 133 
concentrations of the following: total antioxidant status (TAS), uric acid, glucose, insulin, insulin resistance 134 
[evaluated by the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index], total cholesterol, 135 
high-density-lipoprotein (HDL)-cholesterol, triglycerides, aspartate aminotransferase (AST), alanine 136 
aminotranferase (ALT), and γ-glutamyl transferase (GGT). In addition, differences in weight, waist 137 
circumference, and arterial blood pressure were also explored. 138 
Intervention 139 
The subjects were randomly allocated into the “resveratrol-first” group or the “placebo-first” group. Subjects in 140 
the “resveratrol-first” group received 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia 141 
Bioceuticals LLC, one tablet/day in the morning after fasting overnight); 30 days of wash-out (no 142 
supplementation), and 30 days of treatment with placebo (one tablet/day in the morning after fasting overnight). 143 
Subjects in the “placebo-first” group received 30 days of treatment with placebo (one tablet/day in the morning 144 
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after fasting overnight); 30 days of wash-out (no supplementation), and then 30 days of treatment with 145 
Transmax (resveratrol, 500 mg, one tablet/day in the morning after fasting overnight). The researches who 146 
administered the tablets to the subjects were blinded to the patient treatment and treatment group. 147 
Time schedule 148 
Fasting blood samples were collected from all subjects in both groups at baseline, after 30-days, after 60-days, 149 
and at the end of the study, as detailed in Figure 1. After each blood sample was collected, the levels of the 150 
following were measured: CRP, TAS, uric acid, glucose, insulin, total cholesterol, HDL-cholesterol, 151 
triglycerides, AST, ALT, and GGT. Data related to health status, the use of drugs or supplements, usual dietary 152 
habits and exercise levels, weight, waist circumference and arterial blood pressure were collected from all 153 
subjects by trained researchers. A food-frequency questionnaire adapted from the EPIC (European Prospective 154 
Investigation into Cancer and Nutrition) questionnaire [16] and focused on dietary polyphenol intake was 155 
distributed to all subjects. Alcohol intake was assessed by multiplying the mean daily consumption for each 156 
beverage by the ethanol content, to give grams of alcohol/day (one can/bottle/glass of beer =13 g, one glass of 157 
wine =12 g, one standard drink of spirit =14 g).  Each nutrient was adjusted for total energy using the residual 158 
method [17]. The exercise level was evaluated in all individuals using the Minnesota-Leisure-Time-Physical-159 
Activity questionnaire [18]. 160 
Compliance with the study protocol and adverse events were monitored by phone calls and questionnaire recalls. 161 
Sample size 162 
At least a 30% reduction in CRP values should be detected, with a power of 80% and a two-tailed 0.05 α-value. 163 
Because the distribution of CRP was highly skewed, the log-transformed value of the CRP concentrations was 164 
used to estimate the sample size by the t-test for paired-data. Given that a 30%-reduction in the non-transformed 165 
CRP level corresponded to an absolute value reduction of –0.36 for log-CRP and that the standard deviation of 166 
log-CRP was 0.9 [13], the effect size to be tested was 0.4. A sample size of 50 subjects (25 in the “resveratrol-167 
first” group and 25 in the “placebo-first” group) was required to obtain an 80% power and a two-tailed α-value 168 
of 0.05.  169 
Randomization and allocation concealment 170 
The random sequence of treatment (resveratrol/placebo or placebo/resveratrol) was computer-generated in the 171 
Epidemiology Unit, using blocks of different lengths (2 and 4) in random order. All subjects involved in the 172 
study had no access to the allocation sequence until the end of the statistical analyses.  173 
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Randomization implementation and blinding 174 
In accordance with the random sequence, a person who did not take part in the study prepared the bottles for the 175 
participants, by putting the tablets of resveratrol and placebo into identical bottles and then applying labels to 176 
identify the participants, and a number (1 or 2) according to the sequence in which the subject should consume 177 
the tablets in each bottle. The participants and the researchers who interviewed and visited the subjects were 178 
blinded to the contents of the bottles. All laboratory measurements were centralized and performed in a blinded 179 
manner. 180 
Ethical considerations 181 
All procedures were in compliance with the principles of the Helsinki Declaration. The study protocol was 182 
approved by the local ethics committee. All participants provided written informed consent to participate in the 183 
study.  184 
Measurements 185 
Serum CRP values were determined using a high-sensitivity latex agglutination assay on HITACHI 911 186 
Analyzer (Sentinel Ch., Milan). The intra-assay and inter-assay coefficients of variation (CVs) were 0.8-1.3% 187 
and 1.0-1.5%, respectively. The TAS measurements were performed with a colorimetric assay (ImAnOx TAS 188 
Kit, Immundiagnostik AG Bensheim, Germany). The serum glucose level was measured by the glucose oxidase 189 
method, and the uric acid, plasma total and HDL-cholesterol, triglyceride, and GGT values by enzymatic 190 
colorimetric assay (HITACHI 911 Analyzer, Sentinel Ch., Milan). The serum insulin level was determined using 191 
a solid phase enzyme-linked immunosorbent assay kit (LDN, Germany; intra-assay CV: 1.8-2.6%, inter-assay 192 
CV: 3.0-6.0%). The AST and ALT values were evaluated with a kinetic determination (HITACHI 911 193 
Analyzer). The HOMA-IR was calculated according to the published algorithm [19].  194 
Statistical analyses 195 
The baseline clinical and laboratory variables are reported using mean and standard deviation (SD) or, for 196 
skewed distributions, median and inter-quartile range. The CRP, insulin, triglyceride, HOMA-IR, AST, ALT, 197 
and GGT values were logarithmically transformed to approximate normal distributions.  198 
The supplementation effect (∆) on each variable was defined as the within subject difference between the 199 
variable value at the end of resveratrol supplementation and the variable value at the end of placebo 200 
administration. In particular, the difference between variable values at blood collection 2 and at blood collection 201 
4 for resveratrol-first group, and the difference between variable values at blood collection 4 and at blood 202 
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collection 2 for placebo-first group (Figure 1) were evaluated. The standardized distributions of the 203 
supplementation effects (∆/(standard deviation (∆)), were represented using box-plots.  204 
General linear models (GLM) with patients as random effects were performed to assess possible period and 205 
carry-over effects and to estimate crude and adjusted supplementation effects and 95% confidence intervals (CI). 206 
To facilitate the interpretation of log-transformed variables, only those variables were expressed as the ratio of 207 
the variable value at the end of the resveratrol supplementation period to the variable value at the end of the 208 
placebo treatment period, calculated as exponential of the difference in the logarithmic values. 209 
To assess the baseline imbalance, a sensitivity analysis was performed: the effect of resveratrol supplementation 210 
was estimated by using the covariance analysis, adjusting by the baseline within-subject differences.  211 
Statistical analyses were performed using Stata 11.2 (StataCorp LP, College Station, Texas). 212 
 213 
Results 214 
Participant flow 215 
Of the 25 participants in the “resveratrol-first” group, 1 was lost during follow-up (he moved away). No 216 
participant discontinued supplementation or was lost during follow-up in the “placebo-first” group. Data from 49 217 
participants were thus analyzed. The flow diagram of the trial is presented in Figure 2. 218 
Baseline data 219 
The baseline clinical and laboratory characteristics of all the enrolled participants by group are shown in Table 220 
1. No meaningful difference was evident between the two groups. The habitual nutrient intake patterns, 221 
particularly the estimated resveratrol intakes, were very similar between the two groups. 222 
Outcomes and estimation 223 
The standardized differences between the value of each variable at the end of the resveratrol supplementation 224 
period and the value of the variable at the end of the placebo treatment period are reported in the box-plot in 225 
Figure 3. The CRP and triglyceride concentrations decreased, whereas the TAS values increased after 226 
resveratrol supplementation; the other variables exhibited minor changes.  227 
Period and carry-over effects were tested for all variables using GLM and the results were not statistically 228 
significant. The crude and adjusted effects of resveratrol supplementation did not differ; therefore, only the 229 
adjusted effects are reported. The CRP and triglyceride concentrations were significantly reduced, and the TAS 230 
values increased after resveratrol supplementation (Table.2). The estimates did not change after performing a 231 
covariance analysis adjusted for the baseline values of the variables. 232 
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Adverse events 233 
No adverse events were reported in either groups after supplementation.  234 
 235 
Discussion 236 
In healthy smokers, a short period of supplementation with resveratrol exerted anti-oxidant effects and induced a 237 
significant reduction in the CRP and triglyceride concentrations, but there were no changes in weight, waist 238 
circumference, blood pressure, or other metabolic variables. Intriguingly, the beneficial changes occurred in 239 
healthy individuals with baseline laboratory variables within the reference range. It is worth testing this 240 
hypothesis in smokers with a chronic inflammatory condition, such as chronic obstructive pulmonary disease.  241 
Anti-inflammatory effects 242 
Both the acute and chronic anti-inflammatory effects of resveratrol have been demonstrated in 10 healthy 243 
subjects [13-14]. However, a phenolic compound containing resveratrol plus vitamin D3, quercetin, and rice 244 
bran phytate did not significantly affect the levels of inflammatory markers in 34 dysmetabolic patients [20], and 245 
150 mg/day of resveratrol did not reduce the CRP level (although it did reduce tumor-necrosis-factor α) in 11 246 
obese men [21]. The results were difficult to compare because different preparations were used with different 247 
resveratrol concentrations: 40mg [13], 100mg [14, 20], and 150mg [21]. Indeed, a mixture containing resveratrol 248 
plus green tea extract, polyunsaturated fatty acids, vitamins, and tomato extract [22], a polyphenol-rich grape 249 
preparation [23], and a grape extract [24] have been shown to exert significant anti-inflammatory effects in 250 
overweight or high-risk patients. These compounds contained a low resveratrol concentration (<10mg), but also 251 
other bioactive substances.  252 
We found a reduction in the CRP concentrations of approximately 50% after one month of resveratrol 253 
supplementation. This effect was superior to the 26% decrease in the CRP values found after one year of 254 
supplementation with a grape nutraceutical containing 8 mg resveratrol [24]. Therefore, it could be hypothesized 255 
that resveratrol has a dose-dependent ability to decrease the levels of stimulatory cytokines which affect the 256 
release of CRP from the liver. 257 
Long-term cigarette smoking determines a persistent inflammatory response in the lung that leads to tissue 258 
damage and dysfunction [25]. CRP, a marker of low grade chronic systemic inflammation, is highly predictive of 259 
the subsequent risk of cardiovascular events, diabetes and the metabolic syndrome in apparently healthy men and 260 
women, and it is increasingly integrated into cardiovascular risk assessment strategies [26-27]. Given the role of 261 
CRP, the identification of strategies that lead to risk reduction in smokers is worth attention. The release of 262 
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inflammatory cytokines by bronchoalveolar lavage fluid macrophages isolated from smokers and patients with 263 
chronic obstructive pulmonary disease was significantly inhibited by resveratrol, thus potentially leading to the 264 
inhibition of neutrophilia and reduced inflammatory cytokine levels in the airways of these patients [15]. 265 
Intriguingly, resveratrol proved more effective than corticosteroids under the same experimental conditions [15].  266 
The cellular effects of resveratrol are quite complex [28]. It interacts with multiple receptors and enzymes, and in 267 
particular, it stimulates the activities of sirtuin 1 (SIRT1) and adenosine monophosphate-activated protein kinase, 268 
both of which regulate metabolism in many tissues. Resveratrol also inhibits cyclooxygenases, adhesion 269 
molecules, inducible NO synthase, and activated immune cells, as extensively reviewed elsewhere [10,29-31]. 270 
The mechanisms by which resveratrol exerts its anti-inflammatory effects in humans may include the following: 271 
the increased expression of SIRT1, with a subsequent reduction in the expression of phosphotyrosine 272 
phosphatase-1B, which is induced by inflammation [13]; the suppression of the intranuclear binding of NFκB, 273 
the major pro-inflammatory transcription factor [13, 22] or the activator protein-1; the suppression of the 274 
expression of two major pro-inflammatory kinases (jun-N-terminal kinase-1 and inhibitor of κB-kinase) [13]; the 275 
suppression of cytokine signaling 3 [13-14], and of pro-inflammatory cytokines by mononuclear cells [13-14]; 276 
the increase in the level of anti-inflammatory eicosanoid production [22]; the up-regulation of anti-inflammatory 277 
genes; and the decreased expression of pro-inflammatory genes [21,23]. Therefore, the activity of resveratrol 278 
cannot be ascribed to a single mechanism of action. 279 
Anti-oxidant effects 280 
A few human studies [13-14,22-23,32] have confirmed the antioxidant effects of resveratrol that were previously 281 
found in experimental or animal studies [33-34]. One of many mechanisms may be responsible: the direct [35] 282 
and indirect suppression of lipid oxidation; a direct reaction with ROS and an interaction with the enzymatic 283 
pathways involved in ROS generation [13,36]; the induction of the transcription factor -nuclear factor (erythroid-284 
derived 2)-like 2 (Nrf-2)- which activates the transcription of a series of antioxidant genes [14]; or the down-285 
regulation of the expression of pro-oxidant genes [22]. In addition, a pro-oxidant activity has reported for 286 
resveratrol, and this activity is cell-type dependent [6]. In airway cells, resveratrol helps counteract the oxidative 287 
stress generated by cigarette smoking by inducing Nrf2 activation, leading to greater antioxidant defense [37]. 288 
Furthermore, in lungs exposed to smoke, the SIRT1 levels are decreased and undergo post-traslational 289 
oxidative/nitrosative modifications [33] and the histone deacetylase activity (which is inhibited by oxidative 290 
stress and is responsible for the reduced responsiveness to glucocorticoids in smokers) is decreased [6]. By 291 
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activating of SIRT1 and modulating histone deacetylase  activity, resveratrol can attenuate smoke-induced 292 
damage [6,33].  293 
Change in the triglyceride concentrations 294 
Resveratrol supplementation significantly reduced the triglyceride levels in our study population. Significant 295 
changes in the concentrations of medium and long chain triglycerides, decreased apolipoprotein C-III (apo CIII) 296 
and hepatic acyl-CoA cholesterol acyl-transferase activity, and the up-regulation of genes involved in lipid 297 
metabolism, resulting in a reduction in plasma triglycerides, have been observed after resveratrol 298 
supplementation [22-23]. Timmers has hypothesized that fat is liberated from peripheral depots to be 299 
metabolized by the muscle after resveratrol supplementation, as suggested by the increased intramyocellular 300 
lipid levels, improved muscle fat oxidative capacity, and reduced intrahepatic lipid content and plasma 301 
triglyceride concentrations [21]. Thus, resveratrol has been suggested to mimic the effects of endurance training 302 
[21].  303 
Other variables 304 
We did not find any effects of resveratrol on other metabolism-related variables. Increased HDL-cholesterol and 305 
apolipoprotein A1 (apo A-1) values [22,24], reduced LDL-cholesterol levels [23-24], decreased oxidized-LDL 306 
[24] and glucose concentrations [23], improved insulin sensitivity [38], reduced arterial blood pressure and 307 
reduced hepatic liver content [21] have reported. However, other authors did not find any effects on body weight 308 
[20-21], blood pressure, insulin resistance, the lipid profile [20], or the glucose [24], and insulin values [38]. 309 
These differences might be due to the preparations used, with contained different concentrations of resveratrol or 310 
other substances (e.g. fish oil, green tea, antioxidant vitamins), the different durations of the follow-up, and, 311 
above all, the different populations studied. Other cohorts included overweight [21-24], hypertensive [24], or 312 
diabetic [24,37] individuals. Therefore, it could be more difficult to improve values that are already within the 313 
reference range at baseline, as in the case of our patients. We observed minor variations in the liver enzyme 314 
values, in line with the results of another study [24], suggesting that resveratrol does not harm the liver.  315 
Limitations 316 
We could not evaluate compliance with the study protocol, because plasma resveratrol concentrations were not 317 
measured. Nevertheless, the variations in the TAS values, which were measured in a blind manner, were 318 
consistent with the use of resveratrol or placebo according to the study protocol. The short follow-up period 319 
prevented us from reaching conclusions about the long-term effects and safety of resveratrol. However, a one-320 
year supplementation study with 8 mg resveratrol reported no adverse events [24] and a short-term study with 321 
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high doses (2.5-5g/day) found minor gastrointestinal effects [39]. Four-weeks of supplementation with 1g of 322 
resveratrol modulated the enzyme systems involved in detoxification, which could potentially lead to adverse 323 
reactions or altered efficacy of drugs [40]. The optimal dose of resveratrol has yet to be established in human 324 
studies, as recently reported in a systematic review [41].    325 
Conclusions 326 
These results add a small piece to the published evidence about the potential health benefits of resveratrol in 327 
humans, but clearly indicate the need for further trials in patients with chronic diseases or conditions, before this 328 
substance can be recommended for disease prevention or treatment in smokers.   329 
 330 
Abbreviations: alanine aminotranferase (ALT), aspartate aminotransferase (AST), body mass index (BMI), 331 
coefficient of variation (CV), confidence intervals (CI),  C-reactive protein (CRP), European Prospective 332 
Investigation into Cancer and Nutrition(EPIC),  γ-glutamyl transferase (GGT), high-density cholesterol (HDL), 333 
homeostasis model assessment of insulin resistance (HOMA-IR), general linear models (GLM), nuclear factor 334 
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Figure.1 Time schedule of the study 
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Figure.2 Flow of the participants. 
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Table 1. Baseline clinical and laboratory characteristics of the enrolled patients. 
 Total Placebo-first Resveratrol-first 
Age (years)  35.0 [9.8]2 35.4 [10.4] 34.7 [9.4] 
Males (%) 15 [34.0] 8 [36.0] 7 [32.0] 
Dietary variables1:    
Energy (Kcal/day) 2089.6 [692.1] 2070.5 [497.8] 2108.7 [854.1] 
Protein (% energy) 16.3 [2.4] 16.3 [2.3] 16.2 [2.5] 
Carbohydrates (% energy) 47.1 [7.6] 46.9 [8.7] 47.2 [6.5] 
Fiber (g/day) 25.7 [10.4] 24.8 [7.9] 26.6 [12.5] 
Alcohol (g/day) 13.5 [7.4] 13.5 [7.1] 13.6 [7.8] 
Resveratrol (mg/day) 0.9 [1.0] 0.9 [0.9] 0.9 [1.1] 
Metabolic equivalent task (h/week) 78.5 [50.7] 78.3 [49.8] 78.6 [52.3] 
Years of smoking 18.6 [10.4] 18.6 [11.2] 18.5 [9.8] 
CRP (mg/L)3 0.8 [1.6] 0.8 [1.3] 0.8 [1.8] 
TAS (µmol/L) 256.8 [42.5] 253.5 [41.3] 260.2 [44.2] 
Uric acid (mg/dL) 3.5 [0.9] 3.4 [1.0] 3.5 [0.9] 
Fasting glucose (mg/dL) 84.8 [9.7] 84.6 [8.1] 84.9 [11.2] 
Fasting insulin (µU/mL) 3  7.4 [3.1] 7.8 [4.2] 7.4 [2.4] 
HOMA-IR (mmol/L x µU/mL) 3 1.5 [0.7] 1.6 [0.8] 1.5 [0.8] 
Total cholesterol (mg/dL) 199.2 [37.7] 198.5 [35.3] 199.9 [40.7] 
HDL cholesterol (mg/dL) 50.2 [10.6] 50.8 [10.4] 49.7 [11.1] 
Triglycerides  (mg/dL) 3 78.0 [46.0] 77.0 [28.0] 90.0 [56.0] 
AST (U/L) 3 28.0 [13.0] 27.0 [14.0] 29.0 [9.0] 
ALT (U/L) 3 18.0 [10.0] 18.0 [10.0] 19.0 [10.0] 
GGT (U/L) 3 17.0 [6.0] 18.0 [5.0] 17.0 [8.0] 
Weight (kg) 65.4 [11.7] 66.3 [13.8] 64.5 [9.4] 
Body mass index (kg/m2) 23.0 [3.4] 23.1 [3.6] 23.0 [3.2] 
Waist circumference (cm) 79.2 [10.6] 80.2 [12.5] 78.2 [8.4] 
Systolic pressure (mmHg) 117.8 [10.3] 118.4 [11.2] 117.2 [9.5] 
Diastolic pressure (mmHg) 76.4 [7.0] 75.7 [6.6] 77.0 [7.5] 
1Nutrient dietary intake was energy-adjusted 2 Mean [SD] (all such values, with the exception of variables 
marked with3) 3 Median [inter-quartile range] Alanine aminotranferase (ALT); aspartate aminotransferase (AST); 




Table 2. Adjusted estimated effects of resveratrol supplementation as difference
1
 (left) and ratio
 
(right) 
from effects of placebo administration. 
   Effects 
(difference)  
95% CI  p-value Effects 
(ratio)   
95% CI 
CRP 2 -0.75 [-0.97,-0.54] <0.001 0.47 [0.38,0.59] 
TAS 74.2 [60.8,87.6] <0.001   
Uric acid -0.10 [-0.42,0.22] 0.53   
Fasting glucose  -2.6 [-6.3,0.99] 0.15   
Fasting insulin1 -0.06 [-0.14,0.02] 0.14 0.94 [0.87,1.0] 
HOMA-IR2 -0.10 [-0.21,0.01] 0.07 0.91 [0.81,1.0] 
Total cholesterol  0.03 [-7.2,7.3] 0.99   
HDL cholesterol  -0.61 [-2.9,1.7] 0.59   
Triglycerides 2 -0.35 [-0.44,-0.25] <0.001 0.71 [0.65,0.78] 
AST2 -0.06 [-0.14,0.02] 0.15 0.94 [0.87,1.0] 
ALT2 -0.06 [-0.18,0.06] 0.31 0.94 [0.83,1.1] 
GGT2 0.01 [-0.04,0.06] 0.82 1.0 [0.96,1.1] 
Weight  0.23 [-0.29,0.76] 0.39   
BMI 0.07 [-0.10,0.24] 0.44   
Waist circumference -0.14 [-0.98,0.71] 0.75   
Systolic pressure  1.1 [-2.0,4.1] 0.51   
Diastolic pressure  0.17 [-1.5,1.8] 0.84   
1Adjusted estimated effects of resveratrol supplementation as difference (left) and ratio (right) from effects of 
placebo administration; 95% CI and p-values were estimated by general linear models with patients as random 
effects, adjusted for period and carry-over effects.  
2 log-transformed variable 










Legend to Figure 3. 
Box-plots of standardized supplementation effects (∆/(standard deviation (∆)); 5th and 95th percentile (⊥), upper 
and lower quartile (); median (); 1log-transformed values. 
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